News by Tag: Biosimilar Industry
Gain a Deep Insight into the Global Healthcare Cold Chain Logistic Services Market
March 19, 2012
Driven by a strong demand of biopharmaceuticals, vaccines and clinical trial materials; the global market for healthcare cold chain logistic services is expected to grow exponentially in the coming years.
March 19, 2012
Driven by a strong demand of biopharmaceuticals, vaccines and clinical trial materials; the global market for healthcare cold chain logistic services is expected to grow exponentially in the coming years.
Biosimilar Insulin Products in the US to Grow at a CAGR of 74 Percent over the Period 2013-2020
January 25, 2012
Lantus is expected to be the most lucrative target for biosimilar manufacturers and account for 71% of the total biosimilar Insulin sales by 2020.
January 25, 2012
Lantus is expected to be the most lucrative target for biosimilar manufacturers and account for 71% of the total biosimilar Insulin sales by 2020.
The Penetration of Biosimilars in the US Will Vary Across Different Biological Classes
January 19, 2012
The volume penetration of biosimilars in the US will strongly depend upon the complexity of the molecule, the patient pool that it caters and the extent of savings it brings to payers and providers
January 19, 2012
The volume penetration of biosimilars in the US will strongly depend upon the complexity of the molecule, the patient pool that it caters and the extent of savings it brings to payers and providers
Biosimilar/Follow-on Monoclonal Antibodies: The Next Big Thing for Generic Manufacturers
November 1, 2011
With the patents of all major monoclonal antibodies set to expire during 2015 - 2020, Biosimilar (or Follow-on) Monoclonal Antibodies are expected to represent the next big thing for generic manufacturers.
November 1, 2011
With the patents of all major monoclonal antibodies set to expire during 2015 - 2020, Biosimilar (or Follow-on) Monoclonal Antibodies are expected to represent the next big thing for generic manufacturers.
IMARC Group Releases the Most Robust Long Range Market Forecast on the US Biosimilar/Follow-on Biologics Market
October 24, 2011
With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate.
October 24, 2011
With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate.